X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Stock Report

Market Cap: US$386.5m

X4 Pharmaceuticals Future Growth

Future criteria checks 2/6

X4 Pharmaceuticals is forecast to grow earnings and revenue by 35.5% and 53.1% per annum respectively. EPS is expected to grow by 63.7% per annum. Return on equity is forecast to be -46.2% in 3 years.

Key information

35.5%

Earnings growth rate

63.71%

EPS growth rate

Biotechs earnings growth23.8%
Revenue growth rate53.1%
Future return on equity-46.21%
Analyst coverage

Low

Last updated05 Dec 2025

Recent future growth updates

Recent updates

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors

Aug 12
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
User avatar

US Launch And EMA Approval Will Expand Global Reach

The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

Sep 19

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

Jul 20

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Earnings and Revenue Growth Forecasts

NasdaqCM:XFOR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202718-98-83-833
12/31/202611-96-87-874
12/31/202534-81-105-1054
9/30/202534-95-106-103N/A
6/30/202533-102-112-109N/A
3/31/20253115-120-110N/A
12/31/20243-37-138-131N/A
9/30/20241-17-133-126N/A
6/30/2024118-120-112N/A
3/31/2024N/A-129-104-104N/A
12/31/2023N/A-101-97-97N/A
9/30/2023N/A-111-88-88N/A
6/30/2023N/A-131-86-86N/A
3/31/2023N/A-96-83-83N/A
12/31/2022N/A-96-77-77N/A
9/30/2022N/A-103-77-77N/A
6/30/2022N/A-102-72-72N/A
3/31/2022N/A-100-73-73N/A
12/31/2021N/A-103-72-71N/A
9/30/2021N/A-85-70-69N/A
6/30/2021N/A-82-71-69N/A
3/31/2021N/A-78-63-62N/A
12/31/20203-62-60-59N/A
9/30/20203-55-52-51N/A
6/30/20203-55-50-49N/A
3/31/20203-53-53-52N/A
12/31/2019N/A-53-48-48N/A
9/30/2019N/A-55-46-46N/A
6/30/2019N/A-46N/A-39N/A
3/31/2019N/A-40N/A-31N/A
12/31/2018N/A-36N/A-25N/A
9/30/2018N/A-31N/A-23N/A
12/31/2017N/A-25N/A-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XFOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XFOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XFOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XFOR's revenue (53.1% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: XFOR's revenue (53.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: XFOR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 05:16
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

X4 Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leah Rush CannBrookline Capital Markets
Arlinda LeeCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.